Mammazentrum Hamburg MVZ GbR — Clinical Trial Site

36 Registered trials

21 Currently recruiting

Organisation

Mammazentrum Hamburg MVZ GbR

Location

Hamburg, Germany

Identifier

ORG-100045682

Address

Moorkamp 2-6, Eimsbuettel, 20357, Germany

Departments

-
049029
Am Krankenhaus Jerusalem
Breast Center
Breast Clinic (Klinik fuer Frauenheilkunde/Brustzentrum)
Breast Oncology
Brustklinik
Brustklinik am Krankenhaus Jerusalem
Brustzentrum
Gynäkologisches Operationszentrum Hamburg
Gynäkologisches und Onkologisches Therapie- und Operationszentrum
Gynecology
Mammazentrum
Mammazentrum Hamburg am Krankenhaus Jerusalem
Mammazentrum Hamburg MVZ GbR
Mammazentrum HH
Mammazentrum HH am Krankenhaus Jerusalem
Medicine
N.A.
N/A
NA
Oncology
Onkologie
Operative Therapie und Onkologie

Clinical trials at this site (36)

Search interface

BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab… Pending

2024-516236-10-00 Triple-negative breast cancer 4
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit… Recruiting

2025-523204-68-00 HER2-positive breast cancer 4 2026-03-25
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting

2022-501152-28-00 Breast Cancer 4 2022-12-21
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in pa… Recruiting

2024-511392-15-00 HR+/HER2- advanced breast cancer 5 2025-11-20
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer Recruiting

2024-514822-21-00 Platinum-resistant Ovarian Cancer 5 2025-10-02
A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an… Recruiting

2024-516162-11-00 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3 5 2025-07-14
A trial to learn how well saruparib with camizestrant works and how safe it is in adults with advanced breast cancer that is hormone recepto… Recruiting

2023-504180-16-00 Advanced Breast Cancer 5 2025-04-07
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer-… Recruiting

2023-509292-17-00 primary high-risk lobular breast cancer 4 2024-11-08
NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br… Recruiting

2023-508787-29-00 Triple-negative early breast cancer with low risk for r 4 2024-10-10
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with … Recruiting

2024-511780-28-00 Patients with presumed and previously untreated advance 4 2022-05-05
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended

2023-507306-13-00 HER2-positive unresectable locally recurrent or metasta 4 2025-04-13
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 HER2+ early breast cancer 4 2024-02-05